Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Active, not recruiting · NCT02663297 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-10-01 | NCT02663297 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | Chapel Hill | United States | 7 |
| Wake Forest University | Winston-Salem | United States | 22 |